A novel K-ras mutation in colorectal cancer. A case report and literature review

Raffaele Palmirotta, Annalisa Savonarola, Vincenzo Formica, Giorgia Ludovici, Girolamo Del Monte, Mario Roselli, Fiorella Guadagni

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background: Activating mutations in the K-ras oncogene mainly occurr in codons 12 and 13 and may be predictive of response to drugs directly linked to the K-ras signaling pathway, such as panitumumab and cetuximab. Materials and Methods: K-ras analysis was carried out on DNA extracted from paraffin-embedded tumor samples after microdissection. Exons 1 and 2 were amplified by PCR and then sequenced. Results: A never-reported K-ras mutation (CAG>TAG) determining a premature stop signal at codon 22 (Gln22Stop) was found in a patient with metastatic colorecta cancer. BRAF and p53 were not found to be modified and microsatellite instability was not present. The patient, however, was found to be unresponsive to an anti-EGFR MAb treatment. Conclusion: This study is the first report of a novel K-ras truncating mutation in a patient with metastatic colorectal cancer and is also suggestive for the evaluation of alternative pathways to better identify individuals who are likely to benefit from targeted therapies.

Original languageEnglish
Pages (from-to)3369-3374
Number of pages6
JournalAnticancer Research
Volume29
Issue number8
Publication statusPublished - Aug 2009

Fingerprint

Colorectal Neoplasms
Codon
Mutation
Microdissection
Microsatellite Instability
ras Genes
Paraffin
Exons
Neoplasms
Polymerase Chain Reaction
DNA
Therapeutics
Pharmaceutical Preparations
panitumumab
Cetuximab

Keywords

  • Colorectal cancer
  • K-ras
  • Panitumumab

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Palmirotta, R., Savonarola, A., Formica, V., Ludovici, G., Del Monte, G., Roselli, M., & Guadagni, F. (2009). A novel K-ras mutation in colorectal cancer. A case report and literature review. Anticancer Research, 29(8), 3369-3374.

A novel K-ras mutation in colorectal cancer. A case report and literature review. / Palmirotta, Raffaele; Savonarola, Annalisa; Formica, Vincenzo; Ludovici, Giorgia; Del Monte, Girolamo; Roselli, Mario; Guadagni, Fiorella.

In: Anticancer Research, Vol. 29, No. 8, 08.2009, p. 3369-3374.

Research output: Contribution to journalArticle

Palmirotta, R, Savonarola, A, Formica, V, Ludovici, G, Del Monte, G, Roselli, M & Guadagni, F 2009, 'A novel K-ras mutation in colorectal cancer. A case report and literature review', Anticancer Research, vol. 29, no. 8, pp. 3369-3374.
Palmirotta R, Savonarola A, Formica V, Ludovici G, Del Monte G, Roselli M et al. A novel K-ras mutation in colorectal cancer. A case report and literature review. Anticancer Research. 2009 Aug;29(8):3369-3374.
Palmirotta, Raffaele ; Savonarola, Annalisa ; Formica, Vincenzo ; Ludovici, Giorgia ; Del Monte, Girolamo ; Roselli, Mario ; Guadagni, Fiorella. / A novel K-ras mutation in colorectal cancer. A case report and literature review. In: Anticancer Research. 2009 ; Vol. 29, No. 8. pp. 3369-3374.
@article{5b7659a7dd0944f2b1c7789670648e46,
title = "A novel K-ras mutation in colorectal cancer. A case report and literature review",
abstract = "Background: Activating mutations in the K-ras oncogene mainly occurr in codons 12 and 13 and may be predictive of response to drugs directly linked to the K-ras signaling pathway, such as panitumumab and cetuximab. Materials and Methods: K-ras analysis was carried out on DNA extracted from paraffin-embedded tumor samples after microdissection. Exons 1 and 2 were amplified by PCR and then sequenced. Results: A never-reported K-ras mutation (CAG>TAG) determining a premature stop signal at codon 22 (Gln22Stop) was found in a patient with metastatic colorecta cancer. BRAF and p53 were not found to be modified and microsatellite instability was not present. The patient, however, was found to be unresponsive to an anti-EGFR MAb treatment. Conclusion: This study is the first report of a novel K-ras truncating mutation in a patient with metastatic colorectal cancer and is also suggestive for the evaluation of alternative pathways to better identify individuals who are likely to benefit from targeted therapies.",
keywords = "Colorectal cancer, K-ras, Panitumumab",
author = "Raffaele Palmirotta and Annalisa Savonarola and Vincenzo Formica and Giorgia Ludovici and {Del Monte}, Girolamo and Mario Roselli and Fiorella Guadagni",
year = "2009",
month = "8",
language = "English",
volume = "29",
pages = "3369--3374",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "8",

}

TY - JOUR

T1 - A novel K-ras mutation in colorectal cancer. A case report and literature review

AU - Palmirotta, Raffaele

AU - Savonarola, Annalisa

AU - Formica, Vincenzo

AU - Ludovici, Giorgia

AU - Del Monte, Girolamo

AU - Roselli, Mario

AU - Guadagni, Fiorella

PY - 2009/8

Y1 - 2009/8

N2 - Background: Activating mutations in the K-ras oncogene mainly occurr in codons 12 and 13 and may be predictive of response to drugs directly linked to the K-ras signaling pathway, such as panitumumab and cetuximab. Materials and Methods: K-ras analysis was carried out on DNA extracted from paraffin-embedded tumor samples after microdissection. Exons 1 and 2 were amplified by PCR and then sequenced. Results: A never-reported K-ras mutation (CAG>TAG) determining a premature stop signal at codon 22 (Gln22Stop) was found in a patient with metastatic colorecta cancer. BRAF and p53 were not found to be modified and microsatellite instability was not present. The patient, however, was found to be unresponsive to an anti-EGFR MAb treatment. Conclusion: This study is the first report of a novel K-ras truncating mutation in a patient with metastatic colorectal cancer and is also suggestive for the evaluation of alternative pathways to better identify individuals who are likely to benefit from targeted therapies.

AB - Background: Activating mutations in the K-ras oncogene mainly occurr in codons 12 and 13 and may be predictive of response to drugs directly linked to the K-ras signaling pathway, such as panitumumab and cetuximab. Materials and Methods: K-ras analysis was carried out on DNA extracted from paraffin-embedded tumor samples after microdissection. Exons 1 and 2 were amplified by PCR and then sequenced. Results: A never-reported K-ras mutation (CAG>TAG) determining a premature stop signal at codon 22 (Gln22Stop) was found in a patient with metastatic colorecta cancer. BRAF and p53 were not found to be modified and microsatellite instability was not present. The patient, however, was found to be unresponsive to an anti-EGFR MAb treatment. Conclusion: This study is the first report of a novel K-ras truncating mutation in a patient with metastatic colorectal cancer and is also suggestive for the evaluation of alternative pathways to better identify individuals who are likely to benefit from targeted therapies.

KW - Colorectal cancer

KW - K-ras

KW - Panitumumab

UR - http://www.scopus.com/inward/record.url?scp=68549090700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68549090700&partnerID=8YFLogxK

M3 - Article

C2 - 19661358

AN - SCOPUS:68549090700

VL - 29

SP - 3369

EP - 3374

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 8

ER -